Y-mAbs Therapeutics Inc
NASDAQ:YMAB

Watchlist Manager
Y-mAbs Therapeutics Inc Logo
Y-mAbs Therapeutics Inc
NASDAQ:YMAB
Watchlist
Price: 4.52 USD 1.8%
Market Cap: 204.7m USD

EV/EBITDA
Enterprise Value to EBITDA

-4.7
Current
-4.9
Median
4.7
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-4.7
=
Enterprise Value
144.2m USD
/
EBITDA
-30.4m USD
EBITDA Growth EV/EBITDA to Growth
US
Y-mAbs Therapeutics Inc
NASDAQ:YMAB
Average EV/EBITDA: 15.9
Negative Multiple: -4.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 751.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.5
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.4
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.2
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -577.1 N/A N/A
AU
CSL Ltd
ASX:CSL
17.3
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.1
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.1 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -683.9 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-2.8
2-Years Forward
EV/EBITDA
-3.1
3-Years Forward
EV/EBITDA
-4.4